trending Market Intelligence /marketintelligence/en/news-insights/trending/mbrcuhmij4rw6qii11z2ya2 content esgSubNav
In This List

Aileron Therapeutics CEO resigns; interim replacement named

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Aileron Therapeutics CEO resigns; interim replacement named

Joseph Yanchik III resigned as president, CEO and director of Aileron Therapeutics Inc.

The clinical-stage biopharmaceutical company named John Longenecker as interim CEO. Longenecker is the founder and president of JPL Biotech, a biopharma/pharmaceutical consulting company.